Physician profile
Jonathan A Altman
NPI 1457327827
$517.99
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $116 · 2021: $66.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $137.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $96.94 | 2019 | |
| Daiichi Sankyo INC. | $41.84 | 2019-2020 | |
| Novo Nordisk INC | $37.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $31.08 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.85 | 2019 | |
| Allergan, INC. | $24.86 | 2020 | |
| Merck Sharp & Dohme LLC | $15.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.55 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.06 | 2021 | |
| Alkermes, INC. | $12.85 | 2019 | |
| Abbvie INC. | $12.19 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.